Skip to main content

Table 4 Triggers to treatment used in patients under Active Surveillance

From: Active surveillance of prostate cancer: a questionnaire survey of urologists, clinical oncologists and urology nurse specialists across three cancer networks in the United Kingdom

Publication

Gleason Score on repeat biopsy

Positive cores

% cancer involvement per single core

% positive biopsy cores

PSAdt cT (years)

PSAv (ng/ml/year)

cT

Dall’Era [11]

Progression

-

-

-

-

>0.75

-

Tosoian [18]

>6

>2

>50

-

-

-

-

Ercole [13]

Progression

Increase

Increase

-

-

-

Upstage

Klotz [14]

≥4

-

-

-

3

-

-

Ischia [15]

Progression

-

-

-

-

-

Upstage

Thomsen [16]

≥3 + 4

>3

-

-

3

-

Upstage

Selvadurai [17]

≥4 + 3

-

-

>50

-

>1

-

  1. cT clinical tumour category, PSAdt prostate-specific antigen doubling time, PSAv PSA velocity